Hubei Guangji Pharmaceutical Co., Ltd. (000952.SZ) Latest Company News

Oct 29, 2026, 11:12 UTC
Guangji Pharmaceutical's wholly owned subsidiary Jikang Company agreed to transfer a 51% stake in Changjiang Guangji to Changjiang Medical Investment for RMB 1.912602 million, leaving Jikang with 49% and removing Changjiang Guangji from Guangji Pharmaceutical's consolidated statements.
Source:
- finance.sina.cn
Oct 29, 2026, 11:09 UTC
Guangji Pharmaceutical reported third-quarter 2026 revenue of 123 million yuan, down 14.78% year over year, and a net loss attributable to shareholders of 1.9608 million yuan; for the first three quarters, revenue was 435 million yuan and the net loss was 59.9059 million yuan.
Source:
- finance.sina.cn
Sep 15, 2026, 10:58 UTC
Guangji Pharmaceutical announced it plans to publicly list and transfer its 49% stake in Hubei Changtou Anhua Hotel Co., Ltd. on the Wuhan Optics Valley United Property Rights Exchange, with a listing price no lower than RMB 22.1378 million; after the transaction the company will no longer hold any shares in Changtou Anhua Hotel.
Source:
- finance.sina.cn
Aug 27, 2026, 08:07 UTC
Guangji Pharmaceutical announced its first-half 2026 results, reporting a net loss attributable to shareholders of 57.9451 million yuan, compared with a loss of 75.5151 million yuan in the same period of 2025.
Source:
- finance.sina.cn
Aug 27, 2026, 03:54 UTC
Guangji Pharmaceutical announced that its application for a 2026 private placement of shares was accepted by the Shenzhen Stock Exchange on August 26, 2026.
Source:
- finance.sina.cn

000952.SZ

Guangji Pharmaceutical's wholly owned subsidiary Jikang Company agreed to transfer a 51% stake in Changjiang Guangji to Changjiang Medical Investment for RMB 1.912602 million, leaving Jikang with 49% and removing Changjiang Guangji from Guangji Pharmaceutical's consolidated statements.

Guangji Pharmaceutical reported third-quarter 2026 revenue of 123 million yuan, down 14.78% year over year, and a net loss attributable to shareholders of 1.9608 million yuan; for the first three quarters, revenue was 435 million yuan and the net loss was 59.9059 million yuan.

Guangji Pharmaceutical announced its first-half 2026 results, reporting a net loss attributable to shareholders of 57.9451 million yuan, compared with a loss of 75.5151 million yuan in the same period of 2025.

Guangji Pharmaceutical announced that its application for a 2026 private placement of shares was accepted by the Shenzhen Stock Exchange on August 26, 2026.